Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascendis Pharma A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.436 Good day and welcome to the third quarter 2025 Ascendus Pharma earnings conference call. 00:00:05.436 -- 00:00:08.459 At this time, all participants are in listen-only mode. 00:00:08.459 -- 00:00:11.962 After the speaker's presentation, there will be a question and answer session. 00:00:11.962 -- 00:00:16.526 To ask a question, please press star 1-1. If your question has been answered and you'd 00:00:16.526 -- 00:00:19.308 like to remove yourself from the queue, press star 1-1 again. 00:00:19.308 -- 00:00:23.592 We ask that you limit yourself to one question and one follow-up. 00:00:23.592 -- 00:00:28.216 I would now like to turn the call over to Chad Fugier, Vice President of Investor Relations 00:00:28.216 -- 00:00:31.718 at Ascendus Pharma. Please go ahead. 00:00:31.840 -- 00:00:37.025 Thank you, Operator, and thank you, everyone, for joining our third quarter 2025 Financial 00:00:37.025 -- 00:00:42.291 Results Conference Call. I'm Chad Fugere, Vice President of Investor Relations at Ascendus 00:00:42.291 -- 00:00:47.135 Pharma. Joining me on the call today are Yen Mickelson, President and Chief Executive 00:00:47.135 -- 00:00:52.401 Officer, Scott Smith, Executive Vice President and Chief Financial Officer, Sherry 00:00:52.401 -- 00:00:57.065 Glass, Chief Business Officer, Jay Wu, EVP and President, U.S. 00:00:57.065 -- 00:01:01.473 Market, and Amy Hsu, EVP and Chief Medical Officer. 00:01:01.473 -- 00:01:05.279 Before we begin, I'd like to remind you that this conference call will contain forward-looking 00:01:05.279 -- 00:01:09.907 statements that are intended to be covered under the safe harbor provided by the Private 00:01:09.907 -- 00:01:14.494 Securities Litigation Reform Act. Examples of such statements may include, but ...